Literature DB >> 23554410

Kba.62 and S100 protein expression in cytologic samples of metastatic malignant melanoma.

Gulsun Erdag1, Sinchita Roy Chowdhuri, Patricia Fetsch, Dana Erickson, Marybeth S Hughes, Armando C Filie.   

Abstract

The diagnosis of melanoma can be challenging, especially in metastatic lesions, due to the ability of melanoma cells to morphologically mimic carcinoma, sarcoma and even lymphoma cells. Moreover, melanomas can exhibit negative immunostaining for the melanoma markers HMB-45 and MART-1/Melan-A, often used in the diagnosis of this tumor. KBA.62 is a recently described antibody that reacts with benign and malignant melanocytic proliferations. In this study, we report our experience with KBA.62 and S100 protein immunostaining in the diagnosis of metastatic melanoma on fine-needle aspiration and effusion samples. We reviewed 60 cytology samples from 58 patients with metastatic melanoma. Our results showed that KBA.62 stained 75% of the cases and S100 protein 87% of the cases. KBA.62 and S100 protein stained the majority of metastatic melanomas that were negative for HMB-45 and MART-1; KBA.62 stained 73% of the cases and S100 protein 73% of the cases. The majority (85%) of the cases negative for HMB-45 and MART-1 were positive for KBA.62 and/or S100 protein. Additionally, we also observed that KBA.62 staining was positive in the majority of epithelioid and spindle cell type melanoma cells. In conclusion, the performances of KBA.62 and S100 protein were similar and both markers are useful in the diagnosis of metastatic melanoma in cytology material, especially when the tumor cells lack expression of HMB-45 and MART-1.
Copyright © 2012 Wiley Periodicals, Inc., a Wiley company.

Entities:  

Keywords:  KBA.62; S100 protein; cytology; immunocytochemistry/immunohistochemistry; melanoma

Mesh:

Substances:

Year:  2013        PMID: 23554410      PMCID: PMC7571257          DOI: 10.1002/dc.22948

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  26 in total

1.  Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration.

Authors:  P A Fetsch; F M Marincola; A Filie; Y M Hijazi; D E Kleiner; A Abati
Journal:  Cancer       Date:  1999-02-25       Impact factor: 6.860

2.  KBA62 and PNL2: 2 new melanoma markers-immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics.

Authors:  Phyu Phyu Aung; Maarit Sarlomo-Rikala; Jerzy Lasota; Jin-Ping Lai; Zeng-Feng Wang; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

3.  Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.

Authors:  Xiaowei Xu; Albert Y Chu; Terry L Pasha; David E Elder; Paul J Zhang
Journal:  Am J Surg Pathol       Date:  2002-01       Impact factor: 6.394

4.  Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma.

Authors:  Kim Hookim; Michael H Roh; Joseph Willman; Jeremiah Placido; Helmut C Weigelin; Kristina L Fields; Judy Pang; Bryan L Betz; Stewart M Knoepp
Journal:  Cancer Cytopathol       Date:  2011-07-25       Impact factor: 5.284

5.  Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections.

Authors:  O Kaufmann; S Koch; J Burghardt; H Audring; M Dietel
Journal:  Mod Pathol       Date:  1998-08       Impact factor: 7.842

6.  False-positive rate of the immunoperoxidase stains for MART1/MelanA in lymph nodes.

Authors:  Shaofeng Yan; Jeoffry B Brennick
Journal:  Am J Surg Pathol       Date:  2004-05       Impact factor: 6.394

7.  Fine-needle aspiration biopsy of malignant melanoma: a cytologic and immunocytochemical analysis.

Authors:  T J Simmons; S E Martin
Journal:  Diagn Cytopathol       Date:  1991       Impact factor: 1.582

8.  Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma.

Authors:  N G Ordóñez; X L Ji; R C Hickey
Journal:  Am J Clin Pathol       Date:  1988-10       Impact factor: 2.493

9.  Production and characterisation of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections.

Authors:  E Cohen-Knafo; T al Saati; J Aziza; E Ralfkiaer; J Selves; B Gorguet; G Delsol
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

Review 10.  PEComas: the past, the present and the future.

Authors:  Guido Martignoni; Maurizio Pea; Daniela Reghellin; Giuseppe Zamboni; Franco Bonetti
Journal:  Virchows Arch       Date:  2007-12-14       Impact factor: 4.064

View more
  1 in total

Review 1.  Cytologic diagnosis of metastatic melanoma by FNA: A practical review.

Authors:  Andrea Ronchi; Marco Montella; Federica Zito Marino; Giuseppe Argenziano; Elvira Moscarella; Gabriella Brancaccio; Giuseppe Ferraro; Giovanni Francesco Nicoletti; Teresa Troiani; Renato Franco; Immacolata Cozzolino
Journal:  Cancer Cytopathol       Date:  2021-07-26       Impact factor: 4.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.